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Svensk popula¨rvetenskaplig sammanfattning
Kombinationsterapi inneba¨r att flera la¨kemedel ges samtidigt, vilket go¨rs bland annat
fo¨r uppn˚a ba¨ttre effekt och fo¨r att undvika resistens. Kombinationsterapier blir ofta
komplicerade vad ga¨ller att va¨lja bra la¨kemedel att kombinera samt na¨r och vilka
doser som ska ges. Ista¨llet fo¨r att enbart genomfo¨ra experimentella studier, kan man
anva¨nda matematiska modeller fo¨r att fo¨rso¨ka fo¨rutsp˚a utfall. Detta go¨rs genom att
man kalibrerar en modell till en begra¨nsad ma¨ngd experimentella data och l˚ater
modellen prediktera utfallet av t.ex. en ho¨gre eller la¨gre dos, eller om man doserar
tre g˚anger i veckan ista¨llet fo¨r varje dag.
Den ha¨r avhandlingen betraktar flera matematiska modeller fo¨r kombinationste-
rapi av kemiska substanser, eller kombinationer best˚aende utav en kemisk substans
och str˚alning. Ett genomg˚aende koncept a¨r Tumor Static Exposure (TSE), vilket a¨r
den exponering utav la¨kemedel som go¨r att tumo¨ren varken va¨xer eller krymper. Ger
man ett la¨kemedel a¨r TSE den la¨gsta exponeiring av la¨kemedlet som man beho¨ver
uppn˚a fo¨r att tumo¨ren ska sluta va¨xa, medan om man ger tv˚a la¨kemedel samtidigt,
blir TSE en kurva da¨r alla punkter la¨ngs kurvan har denna egenskap.
Biologiska processer a¨r va¨ldigt komplicerade, varfo¨r man ocks˚a beho¨ver ta ha¨nsyn
till variabilitet mellan individer samt annat osa¨kerhet. Exempelvis kan man ta fram
TSE som predikterar den exponering som kra¨vs fo¨r att tumo¨rerna bo¨rjar krympa fo¨r
90% av populationen.
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Abstract
Mathematical models based on ordinary differential equations, with impulses, are
used to describe tumor growth after different treatment combinations, including
chemicals as well as radiation. The models are calibrated, using a nonlinear mixed-
effects framework, based on time series data of tumor volume from animal experi-
ments. Important features incorporated into the models include natural cell death,
and short-term as well as long-term response to radiation treatment, with or with-
out co-treatment with a radiosensitizing compound. Tumor Static Exposure, defined
as the treatment combinations that yield stability of the trivial solution to the sys-
tem model, is introduced as a prediction tool that can also be used to compare and
optimize combination therapies. The Tumor Static Exposure concept is illustrated
practically, using calibrated models and data from animal experiments, as well as
theoretically, using a linear cell cycle model to describe cancer growth subject to
treatment with an arbitrary number of anticancer compounds.
Keywords: Combination Therapy, Model-Based Drug Development, Non-
linear Mixed-Effects Models, Oncology, Pharmacokinetics/Pharmacodynamics
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1 Prologue
Cancer is one of the leading causes of death worldwide. Cancer is not a single disease,
but more of a collective term for a condition where cells discontinue their normal
responsibilities and start to divide uncontrollably and irrevocably. In most types of
cancers this leads to the formation of lumps, or tumors, consisting of many cancers
cells that no longer act symbiotically with the rest of the body, and only care about
their own proliferation. As the tumor grows large, it puts considerable strain on the
human body, and to make matters worse clusters of cancer cells eventually migrate
to other parts of the body, in search of nutrients and additional spaces to grow. These
clusters traverse by means of the blood stream or lymphatic system and eventually
find themselves occupying critical organs such as the lungs and liver, and as these
organs start to fail, loss of life is inevitable.
The exact causes of cancer are not completely understood, but many genetic as
well as environmental factors have been established. Cancer is closely linked to aging,
not only because older people have had more time to develop cancerous mutations in
their cells, but also because they have been exposed to environmental and life-style
based risk factors for a longer period of time. Aging is also well-known to weaken
the immune system, which increases the likelihood that the body fails to discover
and kill cells that have undergone potentially dangerous mutations that can lead to
cancer.
Cancers are generally treated using one or multiple of the trifecta consisting of
surgery, chemicals, and radiation. The purpose of surgery is to cut out most, if not
all, of the tumor or tumors, and can be preceded (what is known as neoadjuvant
treatment) as well as superseded (what is known as adjuvant treatment) by chemical
intervention and/or radiation. Neoadjuvant treatment usually has the purpose of
temporarily shrinking the tumor to make it easier to cut out, whereas adjuvant
treatment is intended to catch and kill any remnants of cancerous tissues, and to
discourage and prevent recurrences.
Radiation therapy involves bombarding the cancer with high-energy electromag-
netic radiation such as x-rays and gamma rays, or particles such as protons, hoping
to cause enough damage to the cancerous cells that the are eventually destroyed.
Radiation can be given by means of external beam, where one tries to focus as much
of the exposure on the tumor and minimizing the damage causes to the surrounding
healthy tissues, or by internal radiation (what is known as brachytherapy) where a
radioactive device is placed inside the body, close to the cancerous tissue. Approxi-
mately fifty percent of all cancer patients receive radiation treatment at some point,
and sometimes it is the only treatment that is needed.
Last of the trifecta are chemotherapy and various targeted treatments. Chemother-
apy is often described as particularly chosen poison, given in the hopes that the can-
cer is killed or harmed worse before the rest of the body. Targeted treatments are
molecules that bind to a target in a specific gene, protein, or part of the cancer envi-
ronment in order to destabilize cancer growth. In contrast to standard chemotherapy,
targeted treatment do not affect all cells, but instead only a certain subset that is
vulnerable.
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Combination therapy means that two or more cancer treatments are given simul-
taneously, such as a targeted therapy plus chemotherapy or radiation. One important
reason for combination therapies becoming more popular is to combat treatment re-
sistances that can occur during treatment. Some cells carry a mutation that make
them impervious to a particular kind of treatment, so that these cells become domi-
nant over time. However, a multi-pronged attack carried out by different treatments
is less likely to encounter these types of obstacles that would mandate multi-resistant
cancer cells. Another reason for combination therapy is drug synergies, by which is
meant that the effect is greater than some predefined baseline referred to as the ‘ad-
ditive’ effect. What constitutes additivity is somewhat situational, and is wanting
universal agreement.
In this thesis, mathematical models have been constructed based on data from
animal experiments on mice, using a chemotherapeutic known as cisplatin, radiation
therapy in the form of x-rays, a targeted therapy called cetuximab that prevents cell
proliferation, and an early discovery compound that interferes with the repair of DNA
damage, in this case caused by radiation. These data are generated from so-called
xenograft studies, whereupon cancer cells from a patient or cell line are implanted
under skin of the neck or leg of a mouse with a compromised immune system and is
allowed to grow. Tumor size is then measured by caliper which allows for estimation
of tumor volume over time. An experimental study includes a number of animals
divided into different treatment groups. In a combination therapy experiment with
two drugs, there are usually at least four treatment groups: a control, or vehicle group
that does not receive any treatment, a treatment group that receives only one of the
drugs, a treatment group that receives only the other drug, and a treatment group
that receives both drugs.
Mathematical models of tumor growth contain unknown parameters, such as the
doubling time of cancerous cells, and the potency, or efficiency of cell killing, of a
particular chemotherapeutic drug. Plausible values for some of these parameters may
be found in the literature or through other sources, but some need to be estimated
from data. Parameter estimation can be done using a variety of statistical techniques,
the main point being to find the parameter values that minimizes the discrepancy
between model prediction and experimental data. The modeling in this thesis has
invariably made use of so-called mixed-effects modeling, which is a statistical frame-
work that takes into consideration the fact that data comes from a population of
individuals, and that some of the parameters may vary between individuals in the
population. For instance, by looking only at the control group of a xenograft ex-
periment, one finds that tumor growth is approximately exponential. However, the
growth rate, and therefore also the tumor doubling time, is typically different for
different animals.
Mathematical models in pharmacology are not merely used to describe data.
Three main areas of application should be mentioned. The first is to make predic-
tions by simulating models to consider various scenarios using different administration
schedules, or drug combinations. These are typically performed in order to help guide
new experiments to save time and resources. It is also ethically warranted to min-
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imize the number of animals that are sacrificed. The second application is to make
particular kinds of predictions across species, referred to as translations. One can of-
ten find relationships between how certain parameters or responses vary between for
example mouse and man, by considering factors such as heart rate and weight. Since
the mouse has a significantly higher heart rate than the human, physiological and
chemical process occur much faster, and since the mouse is much smaller than the hu-
man, much lower quantities of substances are required to achieve various effects. The
third and last application that we mention is to gain biological insights. Exploration
of a model through mathematical analysis and computer simulation can trigger ques-
tions and hypotheses about the underlying mechanisms and biology that may then be
explored and tested experimentally. For instance, the mechanisms through which a
particular drug operates may not be fully understood, but by creating mathematical
models that are challenged by experimental data, information about which of several
plausible scenarios is most likely can be obtained.
This thesis also discusses the concept of Tumor Static Exposure (TSE). TSE is
the exposure of an anti-cancer drug that leads to stable disease, i.e., when the tumor
is neither growing nor shrinking. Exposure above TSE leads to tumor shrinkage,
whereas exposure below TSE leads to tumor growth. The concept can be naturally
extended to combination therapy with two or more drugs. TSE for a combination of
two drugs consists of all combinations of simultaneous exposures that lead to stable
disease. This is illustrated in Figure 1, taken from paper I, where the horizontal
axis represents the concentration of drug A, and the vertical axis represents the
concentration of drug B. The blue curve is the TSE curve of all concentration pairs
leading to stable disease. It divides the plot into two regions: a red region of exposure
pairs that leads to tumor growth, and a green region of exposure pairs that leads
to tumor shrinkage. These kinds of predictions have been analyzed for each of the
models featured in this thesis.
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Figure 1: Tumor Static Exposure (TSE) curve for combinations of two drugs A and B.
The TSE curve, shown in blue, separates the concentration plane into regions
corresponding to tumor growth (red) and tumor shrinkage (green).
2 Background
Preclinical drug discovery involves experiments performed in vitro, i.e., removed from
their normal biological context, as well as in vivo, i.e., using animal models. In oncol-
ogy, a typical in vivo experiment is the so-called xenograft study, where cancer cells
are placed under the skin of laboratory mice, which are subsequently the recipients
of one or multiple test compounds [35]. By repeated measurements, time series of
tumor volume can be generated with animals divided into treatment groups with
different drugs and administration schedules.
In order to support design and evaluation of such and other experimental studies,
mathematical modeling can be used to predict the outcome in an alternative setting,
e.g., using a different dose, cell line, or drug combination [26, 5]. In fact, modeling
can be particularly helpful in a combination therapy setting owing to the combinato-
rial explosion of combining different drugs as well as doses. Recent decades have also
seen an increased interest in developing combination treatments, as a way to combat
drug resistance and to benefit from drug synergy, i.e., when drugs, in some sense, act
in tandem to produce a greater-than-expected result [63]. A considerable number of
models have been developed and are frequently used to support xenograft studies, c.f.
the review [57]. Nonetheless, with an increasing number of treatment candidates and
modalities, e.g., combinations involving targeted therapy, standard chemotherapy, or
different types of radiation, modeling tools and techniques need to be developed that
can be readily reused for different treatments and cancers [52]. Currently, there is a
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a lack of generic model structures for combination therapies that can be reused for
different combinations, especially combining chemical treatment with e.g. radiation,
and a lack of tools and predictive techniques to select the best combinations. Even
when a good model exists, it is not always clear which predictions are the most appro-
priate and how the model can and should be used to compare and rank combinations,
as well as optimize a given treatment combination.
Dynamics of tumor volume are commonly described by systems of ordinary dif-
ferential equations, with the states constituting a heterogeneous cell population. For
such models, the most important aspects to cover are cell growth due to uncontrolled
mitosis, and the impact of various anti-cancer drugs on the tumor. The models are
calibrated to experimental data using inference techniques ranging from ordinary
least squares to more sophistical frameworks such as nonlinear mixed-effects model-
ing, the latter being well suited to describe variability within and across populations,
and is described in more detailed in Section 8.
The conclusion is then, that in order to produce good predictions, the following
three properties are desirable. First, experiments must be performed that yield infor-
mative data, i.e., with low levels of noise and showing a range of outcomes. Second,
an appropriate model structure is required, preferably with a connection to current
biological understanding, and with a reasonable number of unknown parameters.
Third, an appropriate statistical framework is necessary to calibrate the model and
to capture different aspects such as average behavior, variability, and uncertainty.
Ideally, a positive feedback loop is created, where experimental data is produced,
then analyzed, then new experiments are suggested, informed by modeling, which
leads to a refinement of the model, and so on. In the next section, three research
questions are formulated, each of which is connected to one of the three desirable
properties that have been listed here.
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3 Research questions
The research described in this thesis has been focused on addressing the following
three questions, in the context of preclinical drug discovery and development in on-
cology
• Q1: How can current mathematical models of combination treatments be re-
fined, and what changes should be made to accommodate additional treatments
and treatment modalities?
• Q2: Given a model, what predictions do we use to choose the most promising
combinations for further study and to guide additional study designs?
• Q3: How do we best utilize the statistical framework used for model calibration,
in order to enhance strengths and mitigate weaknesses, with respect to average
behavior, variability, and uncertainty?
3.1 Limitations and scope
This research is on mathematical modeling of combination therapy in oncology, with
an eye towards the preclinical stages of the development cycle. As such, priority
has been given to issues in the intersection of combination therapy and oncology.
Generalization about combination therapy in general, or to other disease areas, have
only received peripheral treatment. Moreover, issues that are particular to the clinical
setting have not been considered, and the important, but difficult, translational step,
from animal to human has not been a primary focus.
The focus has been on describing tumor volume over time, using time series
data from xenograft experiments, and not e.g. models that include spatial tumor
growth. For this reason, and for reasons of accessibility and integrability into existing
drug development processes, the models encountered here are ordinary differential
equations and not partial differential equations. Lastly, the focus has been to model
efficacy, i.e., tumor growth or shrinkage, and not toxicity, although the latter receives
some treatment in the shape of minimization of drug exposure.
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4 Main contributions
In this section we highlight the three main contributions from this thesis, in increasing
order of importance and generality.
4.1 Natural cell death
Paper I introduces natural cell death to a typical tumor growth model with a chain of
damage compartments. This provides a more biologically feasible description of the
tumor where, even in the absence of drug provocation, only a portion of the tumor
cells are actively proliferating. The appropriate initial conditions for such as model
were also a novelty introduced in paper I.
4.2 Modeling of radiation treatment
The second main contribution is the radiation model introduced in paper II, and sub-
sequently modified in paper III. The idea, to allow lethally irradiated cells additional
cell divisions before dying, is not novel, although it is true for the particular imple-
mentation of the idea. Moreover, to the best of our knowledge, these were the first
models to describe xenograft data after radiation therapy in a combination therapy
context, as well as using mixed-effects modeling.
4.3 Tumor Static Exposure
The third contribution, which is developed throughout all five papers contained in
this thesis, is the concept of Tumor Static Exposure (TSE). TSE is defined as the
set of all exposure combinations that result in stable disease, and relates to stability
of the corresponding dynamical system. Aspects considered in this thesis include
practical applications and implementation, generalizations to an arbitrary number of
compounds and to different treatment modalities, convexity and its relationship with
synergy, and treatment optimization via minimization of a weighted total exposure.
4.4 My contributions to the manuscripts
This section is meant to clarify the contributions that I, Tim Cardilin, have made
to the five manuscripts that are part of this thesis. Firstly, I should mention that
I did not take any part in the design, execution, or data collection for any of the
experiments described in the manuscripts, rather data were delivered to me in the
form of excel spreadsheets. I used a Mathematica package developed by Joachim
Almquist, Jacob Leander, and Mats Jirstrand to perform parameter estimation. I
was not part in the development and did not write any of the code, although I
did find and correct several bugs. I frequently consulted the authors, particularly
Joachim Almquist, regarding technical aspects of nonlinear mixed-effects modeling
and the Mathematica implementation. Below follows a summary of my contributions
to each manuscript.
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Paper I: I performed data exploration, modeling fitting, and subsequent analyzes.
I took a leading role in the intellectual effort regarding model construction and re-
lated analysis supported by discussions with Mats Jirstrand, Johan Gabrielsson, and
Joachim Almquist. Discussions were also had with co-authors from Merck KGaA. I
drafted the manuscript, produced all figures, and was responsible for the submission
process through to publication.
Paper II: I performed data exploration, modeling fitting, and subsequent analyzes.
I took a leading role in the intellectual effort regarding model construction and re-
lated analysis supported by discussions with Mats Jirstrand, Johan Gabrielsson, and
Joachim Almquist. Discussions were also had with co-authors from Merck KGaA. I
drafted the manuscript, with the exception of parts related to experimental details
which where partly written by my co-author Astrid Zimmermann, produced all fig-
ures, and was responsible for the submission process through to publication.
Paper III: I performed data exploration, modeling fitting, and subsequent ana-
lyzes. I took a leading role in the intellectual effort regarding model construction and
related analysis supported by discussions with Mats Jirstrand, Johan Gabrielsson,
and Joachim Almquist. Discussions were also had with co-authors from Merck KGaA.
I also drafted the manuscript, produced all figures, and revised it into its current form.
Manuscript IV: I performed data exploration, modeling fitting, and subsequent
analyzes. I took a leading role in the intellectual effort regarding model construction
and related analysis supported by discussions with Mats Jirstrand, Johan Gabriels-
son, and Joachim Almquist. Discussions were also had with co-authors from Merck
KGaA. I drafted the manuscript, with the exception of parts related to experimental
details which where partly written by my co-author Astrid Zimmermann, produced
all figures, and was responsible for the submission process through to publication.
Manuscript V: I choose/found the subject to study. I constructed all proofs, exam-
ples, and mathematical derivations in the manuscript. I also drafted the manuscript
and produced all figures. Discussions and feedback was provided continuously by
Mats Jirstrand and Torbjo¨rn Lundh.
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5 Mathematical Pharmacology
Mathematical pharmacology is defined by the use of advanced mathematical tech-
niques to improve our understanding of pharmacological processes, and should be
regarded as a subdiscipline to mathematical biology. One of the first papers that
mentioned the term was published by van der Graaf, Benson, and Peletier, in 2016,
and discusses, through two examples, how mathematical modeling and analysis can
help improve our understanding of complex biological systems and dynamics [27].
The topic is relatively new and emerging, and is rapidly increasing in popularity, as
can be seen from that fact that it was recently chosen as the subject of a special
issue in the Journal of Pharmacokinetics and Pharmacodynamics, a leading journal
about the modeling of pharmacological processes [39]. The purpose of this section
is illustrate the range of mathematical techniques that have been used to support
pharmacology and drug discovery.
Firstly, we should mention standard pharmacokinetic and pharmacodynamic mod-
eling, which describe what happens to the drug and body, respectively, that typically
utilizes systems of ordinary differential equations as well as standard statistical tech-
niques used to estimate model parameters, ascertain differences between groups, cor-
relation and covariate analyzes, etc [22, 9]. An important framework for such analyzes
is mixed-effects modeling, which is used to quantify differences between individuals
in a population, see e.g., [17] for a classical reference. Modeling and parameter es-
timation has also been considered using stochastic differential equations [41], which
are appropriate when describing dynamics that are inherently non-deterministic, but
which can also be used to correct for model mis-specification. Identifiability analysis
is another area that is used to established whether the parameters in a model can be
estimated given observations about certain quantities, or whether model reduction
may be necessary [32].
Adjacent to identifiability is observability and optimal control theory, which are
used to concoct an optimal treatment regimen, given dynamics described by a math-
ematical model of the disease, various constraints, and an objective function related
to the toxicity and other adverse treatment effects [61, 51].
Partial differential equations have also been successfully used to describe diseases
and treatments, e.g., radiotherapy treatment of brain tumors, supported by medi-
cal imaging techniques (which are also mathematical) to better understand spatial
aspects of cancer growth and migration to different tissues [58].
Other examples include models of target-mediated drug disposition (TMDD),
which describe the binding of a drug molecule to a target, and can be used e.g., to
understand the translation from in vitro (a closed system) to in vivo (an open system)
[24]. These models can be complicated, with many parameters that can be difficult to
properly estimate. However, under certain assumptions that certain processes occur
on different time scales, so-called quasi-equilibrium approximations of the full TMDD
models have also become popular ways to describe the kinetics [44].
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6 Oncology: An Overview
This section gives an overview of the field of oncology, i.e., cancer biology, (diagnosis),
and treatment, with a focus on aspects that are relevant for this thesis. First, we
characterize what is meant by cancer, and follow this up by a brief description of the
cell cycle and some basic facts about tumors. Thereafter, we describe different cancer
treatments, including surgery, chemotherapy, and radiation, which is followed up by
an overview of combination theraphies and related concepts such as drug synergy.
6.1 Hallmarks of cancer
In simple terms, cancer is the name for a class of diseases characterized by uncon-
trolled cell division and invasion to nearby tissues. A more detailed description was
famously proposed by Hanahan and Weingberg in 2000, who defined six hallmarks
of cancer, and in a subsequent update from 2011, included two additional hallmarks
and two enabling traits [29, 30].
The first hallmark, self-sufficiency in growth signals, reflects that cancer cells
are able to go from a resting state to a proliferating state without having been
told to do so through exogenous growth signals. This happens because tumor cells
have developed the ability to generate their own growth signals, creating a positive
feedback loop that reduces the dependence on exogenous factors. An example of this
is epidermal growth factor (EGF), whose receptors (EGFR) are overexpressed on the
surface of many tumor cells. An inhibitor of EGFR, cetuximab, is featured is paper
1, where it is combined with the standard-of-care treatment cisplatin.
The second hallmark, insensitivity to anti-growth signals, means that anti-growth
signals, which can either force a cell into a resting state, or remove its proliferating
capabilities altogether, are disrupted in many cancer cases.
The third hallmark is tissue invasion and metastasis. It is characterized by the
tendency for clusters of cancer cells to migrate from the primary cancer site to other
parts of the body. Metastases allow the cancer to obtain additional nutrient supplies
and space to grow without restriction. Metastatic clusters often travel through the
blood stream or the lymphatic system, which is why swollen lymph nodes close to
the primary site are among the first signs that the disease is starting to spread. It is
for similar reasons that the most common organs for metastases are the lungs and
liver [1].
The forth hallmark concerns the limitless replicative potential of cancer cells.
A non-cancerous cell can divide approximately 60 to 70 times, and each division
carries a loss of telomeres, the ends of the chromosomes, which eventually becomes
unsustainable. Cancer cells, in contrast, have up-regulated telomerase enzyme, and
can activate a mechanism, called alternative lengthening of telomeres (ALT), that
allow telometric information exchange to maintain chromosomal integrity. In this
respect, cancer cells are immortalized and contain limitless replicative potential.
The fifth hallmark describes sustained angiogenesis. Angiogenesis is the process
by which new blood vessels are formed, and is an essential component for any tissue
to grow. In order for the tumor to receive a sufficient supply of oxygen and nutrients,
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angiogenic growth signals are up-regulated compared to normal cells, and similarly,
anti-angiogenic growth signals are disrupted. One example is vascular endothelial
growth factor (VEGF), which is overexpressed in many tumors [13].
The last of the original six hallmarks, evading apoptosis, relates to the vari-
ous strategies which cancers have developed to avoid apoptosis, the process of pro-
grammed cell death that is executed when mutations or DNA damage is detected in
a cell. The cancer must have developed a resistance to apoptosis, either by avoiding
detection, or by disabling the successful executing of the apoptotic process. One ex-
ample is the mutation of the p53 tumor suppressor gene, which is responsible for the
activation of apoptosis [55].
The two additional hallmarks, evading immune response and reprogramming en-
ergy metabolism, reflect the fact that cancer cells must set up a protective barrier, or
a cloak of invisibility, not to be destroyed by the marcophages of the immune system,
and up-regulate energy metabolism to maintain its growth rate. The latter has been
shown to depend greatly on the tumor micro-environment [30].
The two enabling traits, genome instability and tumor-promoting inflammation
help explain how many of the hallmarks listed above come about. Certain mutations,
inherited from a parent cell, can give the daughter cells a selective advantage over
normal cells that allow them to dominate the local environment. Moreover, inflam-
mation from the presence of immune cells have been shown to have pro-tumorigenic
properties, such as providing additional supply of growth factors and enzymes to
facilitate angiogenesis, and releasing chemicals with mutagenic properties.
6.2 Tumor composition and the cell cycle
A cancer tumor is composed of cells that have abdicated their normal responsibilities
in favor or uncontrolled cell division. Tumors are heterogeneous constructions, made
up of different types of cells that serve different functions. The direction of growth,
and consequently the tumor geometry, depends on environmental factors such as
oxygen and nutrient supply. Depending on the homogeneity of the surrounding tissue,
the tumor may be more or less well-approximated by a sphere or an ellipsoid. Many
tumors also contain a necrotic core due to, among other things, hypoxia, i.e., the
inability to supply sufficient amounts of oxygen to the innermost cells [12]. More
generally, the ability to proliferate depends on the location of a cell in the tumor,
with the surface, the outermost layer, having the best opportunity to grow.
The process of mitosis, or the cell cycle, is a complicated process through which
one cell divides into two daughter cells [64]. A simplified description of the process
includes four stages, G1, S, G2, and M, as well as an additional resting stage G0.
Essentially, G1 and G2 represent gaps, or growth phases, between the S and M phases
during which, respectively, DNA synthesis (duplication) and mitosis occur. G1 and
G2 each contain a ‘checkpoint’ to verify cell integrity and that the cell is ready for
the next phase [33].
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6.3 Cancer treatment
Cancer is difficult to treat and is one of the leading cause of dead worldwide, and
has recently overtaken heart disease as the number one killer in the Unites States [1].
There are three principal modes to treat cancer: surgery, chemicals, and radiation.
Surgery aims to cut out as much of, or all, cancerous tissue. It can be preceded
by radiation or chemical intervention in order to shrink the tumor and make it easier
to remove, or superseded by such treatment for prophylactic purposes. Surgery is
the most effective when the disease is localized and has not infiltrated much of the
surrounding tissue, at which point a complete removal can be curative. In contrast,
surgery is much less promising when the cancer has metastasized, since even though
the primary tumor has been cut out, the disease is still present in other parts of the
body. Surgery may still be performed on metastatic cancer patients for palliative rea-
sons, extending life or improving quality-of-life, or with the hope that the remaining
cancer can be treated by other methods.
Chemical intervention can be classified as either chemotherapy, targeted therapy,
hormone therapy, and immunotherapy. Chemotherapy includes compounds that kill
cancer cells as well as normal cells. Due to their accelerated growth rate, cancer
cells are more vulnerable to chemotherapy than many normal cells. However, quickly
proliferating normal cells such as those in the mouth, hair, and intestines are also
particularly sensitive. As such, chemotherapy is poison that aims to kill the cancer
before it kills the patient. Paper I provides an example of a chemotheraputic drug in
cisplatin, a platinum-based compound which interferes with DNA replication. Cis-
platin is used to treat various cancers, including lung cancer and lymphomas. It has
been particularly effective versus testicular cancer, increasing the cure rate from 10%
to 85% [18].
Targeted therapies are molecules that bind to a particular target on the cancer
cell. It works e.g., by inhibiting proliferation or triggering apoptosis in the cell. Tar-
geted therapies are selective and do not typically affect non-cancerous cells. However,
it can sometimes be too selective, affecting only the subset of cancer cells that carry a
certain mutation. Examples of targeted therapies are cetuximab, an EGFR inhibitor,
from paper I, and the early discovery compounds from papers II-IV that interfere
with the repair of DNA damage.
Hormone therapy is the administration or manipulation of hormones to, e.g.,
inhibit the production of a hormone that stimulates cell growth. It can be used to
treat cancers in hormonally sensitive tissues such as the breast, prostate, and adrenal
cortex [20].
Immunotherapy aims to activate or amplify the body’s own immune system to
thwart cancer growth or spread. Recently, a lot of attention has been put on can-
cer immunotherapies, as clinical trials have indicated greatly improved survival for
several different compounds [38].
Finally, radiation treatment involves subjecting the tumor to ionizing radiation,
which can be photons (x-rays or γ-rays), or charged particles such as protons or
electrons [15]. By definition, ionizing radiation creates ions by removing electrons
from atoms and molecules in tissues that are hit by the radiation. This causes damage
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to the DNA of proliferating cells in the form of single or double-strand breaks [65]. In
contrast, cells that are in the resting stage, G0, are less sensitive to radiation. Because
of this, and to give healthy tissue time to heal, radiation is often fractionated into
lower doses of e.g. 2 Gray (Gy), where 1 Gy corresponds to 1 Joule per kilogram of
exposed tissue. The most suitable type of radiation depends on the type of cancer,
with photon radiation being the most commonly used treatment and is the only type
of radiation featured in this thesis.
The linear-quadratic model is an important empirical model used clinically. It
describes the average number of lethal lesions inflicted after radiation dose D as
L = αD + βD2, (1)
where α and β are two parameters that depend on the type of cancer, radiation, tu-
mor composition etc. The standard assumption is that lethal lesions are Poisson dis-
tributed among the cell population [11] and so the probability for a given cell to have
incurred zero lethal lesions, and therefore surviving, is given by exp (−αD − βD2) so
that, by independence, the surviving fraction of cells is given by
SF (D) = exp (−αD − βD2). (2)
While there is no definitive derivation of the linear-quadratic model that has been
confirmed experimentally, a number of derivations have been proposed, e.g. relating
the linear term to lethal lesions inflicted by a single photon, whereas the quadratic
term corresponds to lethal lesions inflicted by two different photons [11, 59].
6.4 Combination therapy
Different drugs or treatments can be combined to create a combination therapy. This
can include a mixture of chemicals and/or radiation. Most combinations include two
different treatments, but triple combinations have also been studied in the clinic [54].
The main reasons why combination treatment could be advantageous compared to
single-agent treatments are to avoid and overcome resistances, reduce toxicity, and
obtain synergistic effects [63].
Drug resistance is a common in oncology, as well as modern medicine in general,
that occurs when a subset of cancer cells carry a mutation that makes them less
sensitive, or impervious, to a particular treatment. As other tumor cells are destroyed
by the treatment, such cells begin to dominate the local tumor environment, which
eventually leads to treatment failure. Combination therapy reduces the risk of such
scenarios, since it would require cells that are resistant to multiple compounds.
There is a possibility to reduce overall toxicity by employing a combination treat-
ment regimen with lower doses. This can be achieved only if the combined toxic
effects of the drugs are tolerable, and the compounds do not produce any undesir-
able toxic interactions. Any treatment is a trade-off between positive and negative
effects, and combination therapy presents a setting with additional degrees of free-
dom on either side, which carries danger as well as opportunity. It therefore becomes
particularly important to have a solid understanding of the individual components
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and their interplay, and to optimize treatment to maximize effects while minimizing
side-effects.
A synergistic effect is one that is greater than some baseline, referred to as the
additive effect. In contrast, a sub-additive effect is referred to as antagonistic. This
reduces the problem to that of defining what it means for a combined drug effect to be
additive. The answer depends on the measured effect, and many different definitions
have been proposed, the two classical definitions being Loewe additivity and Bliss
independence [43, 8]. Loewe additivity, also called dose additivity, applies to drugs
with the same target, in which any convex combination of doses (or concentrations)
with the same effect, should also have the same effect. On the other hand, Bliss
independence applies to drugs with independent target in which case the combined
effect is multiplicative. More complicated models that define synergy have also been
proposed, c.f. [28]. However, one way to look at synergy is that it is an effect that is
greater than expected, but what is expected is conditioned on our understanding of
the drugs and their mechanisms. Since our understanding changes over time, measures
of synergy can therefore be thought of more as a tool to guide and improve said
understanding, than as a therapeutic goal in itself. Therefore, in this thesis, we do
not focus on synergy, but on modeling and quantifying combination effects to aid the
effort to select the best drugs and the best doses or concentrations.
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7 Mathematical modeling of tumor growth
This section gives an overview of the typical mathematical models used in preclinical
drug development, particularly those that are relevant to the manuscripts included in
this thesis. We start with the most general models: systems of impulsive differential
equations, and compartment models, which are ubiquitous in life science. Then, we
move on to a brief overview of the most common pharmacokinetic and pharmaco-
dynamic models, before focusing on tumor growth models, starting with the most
common single state models and moving towards multi-compartment models that
describe drug interventions with chemicals as well as radiation.
7.1 Impulsive differential equations
Models in pharmacotherapy are frequently described by so-called impulsive differen-
tial equations, i.e., equations of the form
x˙(t) = f(t, x(t)), x(t) ∈ Ω ⊂ Rn, t ≥ 0, t 6= τi, (3)
x(τ+i ) = x(τ
−
i ) + gi(x(τ
−
i )), i = 1, 2, ..., (4)
x(0+) = x0, (5)
where x = (x1, ...xn) is an n-dimensional vector of system state variables, t is the
independent variable, invariably used to represent time, f = (f1, ..., fn) is a smooth
vector field, and gi = (gi,1, ..., gi,n), i = 1, 2, ... are smooth functions representing
jumps that occur at times τi, and x0 is the initial state vector. Here, the limit notation
is used for the initial condition in case τi = 0 for some i.
Given that the application is to describe cancer treatment, we need only consider
the case with fixed impulse times, i.e., when τi do not depend on the system state
x, and we can also assume that τi+1 > τi and that τi → +∞, as t → +∞. This
avoids problems with an infinite number of jumps over a finite time interval, and is
fully sufficient for the studied area of application. For equations that satisfy these
assumptions, the standard theory regarding existence and uniqueness of solutions for
ordinary differential equations remains intact, i.e., if f is Lipschitz continuous there
exists a unique solution x(t) to (3) - (5), defined on some maximal interval [0, t+], and
if also for any interval [0, t+], there exists a compact set K ⊂ Ω such that x(t) ∈ K,
for all t ∈ [t0, t+], then there exists a unique solution to (3) - (5) on [0,∞). For
convenience, we also assume that τi 6= 0 for all i and drop the limit notation for the
initial condition. Note that by choosing gi = 0 for all but finitely many i we obtain
an impulsive system with finitely many jumps, and if all gi are chosen to be zero, we
obtain a standard system of ordinary differential equations.
A solution x(t) to (3) - (5) is a piecewise continuous function with potential
discontinuities of the first kind, i.e., jumps, at times τi. The most common type of
jump in pharmacotherapy models is state-independent, due to a bolus dose of a drug.
However, in this thesis we also consider state-dependent jumps due to radiotherapy,
where a fraction of the mass in one state is instantaneously transferred to another
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state. In such cases, for physical reasons, it is important to preserve non-negativity
of the state vector x , i.e., if gi = −kx then k ≤ 1 must hold.
Linear impulsive systems can be written in the form
x˙(t) = A(t)x(t), t 6= τi, (6)
x(τ+i ) = x(τ
−
i ) +Bi x(τ
−
i ), i = 1, 2, ..., (7)
x(0) = x0, (8)
where A and Bi are square matrices. The entries of A may be time-dependent, e.g.,
due to a time-varying drug concentration. For such equations, with fixed impulse
times that satisfy the assumptions listed above, a unique solution always exists on
[0,∞] [3].
Impulsive differential equations can also be written using the Dirac delta dis-
tribution, as was done in paper II. Unfortunately, the notation used in paper II is
erroneous, and we therefore now present the correct formulation. Consider the scalar
equation
x˙(t) = f(t, x(t)) + g(x(t))δ(t− τ), x(0) = x0 (9)
where f and g are globally Lipschitz continuous functions, and τ denotes the time
of the jump. For this equation, Nedeljkov and Oberguggenberger [53] proved that if
the primitive G(x) :=
∫
dx
g(x) is invertible, then
x(τ+) = x(τ−)G−1(G(x(τ−)) + 1). (10)
In this thesis, we are primarily interested in the case g(x) = −ax. Then G(x) =
− 1a lnx and the solution after the jump is given by
x(τ+) = x(τ−)e−a. (11)
Thus, if a > 0 then e−a is the remaining fraction of x after the jump and the removed
fraction is given by (1− e−a). In the next section we introduce compartment models,
a special class of differential equations that are ubiquitous in life sciences.
7.2 Compartment models
This section gives brief description of (linear) compartment models. For a standard
reference, see [31]. Compartment models are systems of differential equations con-
sisting of a number of states xi, referred to as compartments, each representing some
sort of well-mixed materia. The compartments are allowed to interact by exchanging
materia with one another. A general model with n compartments can be written
x˙i = f0i +
n∑
j=1
fji −
n∑
j=1
fij − fi0, i = 1, 2, ..., n, (12)
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where xi is the amount of materia in compartment i, fij ≥ 0 is the flow of materia
from compartment i to compartment j, fi0 ≥ 0 is the flow of materia from com-
partment i to the environment, and f0i ≥ 0 represents the flow of materia from the
environment into compartment i. The flow rates fij = fij(x, t) may in general depend
on the compartment vector x = (x1, ..., xn) as well as time t.
Linear compartment models occur when the flow rates are assumed to be propor-
tional to the amount in outflow compartment, i.e., fij = qijxi, for i = 1, ..., n, j =
0, 1, ..., n, where qij ≥ 0, and f0i = qiixi where qii ≥ 0 in order to allow to for the
possibility that i reacts with itself. The system then becomes linear and homogeneous
and can be described by equation x˙ = Ax, x(0) = x0, where the diagonal entries of
the matrix A are given by
Aii = qii −
n∑
j=1
qij , (13)
and the off-diagonal entries are given by
Aij = qij ≥ 0, i 6= j. (14)
In subsequent sections we present multiple examples of compartment models in order
to describe pharmacokinetics, i.e., what the body does to a drug, as well as pharma-
codynamics, i.e., what the drug does to the body. The contents of these sections can
be found in any standard reference on the subject, e.g. [22] or [9].
7.3 Pharmacokinetic models
Drug effect is often modeled in two steps: first, by a pharmacokinetic model that
connects drug administration to the concentration of drug in the body, and second, by
a pharmacodynamic model that connects drug concentration to an effect of interest,
e.g., tumor growth. Sometimes, when the drug concentration is difficult to measure,
or, as in this thesis, when describing radiation treatment, it is necessary to link drug
administration, i.e., dose, directly to effect.
The pharmacokinetics of a drug can be described by a, usually linear, compart-
ment model where each compartment represents the amount or concentration of the
drug in a different type of tissue. The simplest pharmacokinetic model consists of
a single compartment x representing, e.g., the concentration of a drug in plasma
decaying exponentially over time. The differential equation for this process is
x˙ = −kex, x(0) = D
V
, (15)
where ke is the elimination rate, D is the drug dose, and V is the distribution volume
of x converting dose into concentration. Here, we have assumed that the drug is
administered intravenously such that all of the drug is available in plasma at time
zero. Any type of drug administration that is not intravenous is called extravascular,
e.g., drugs given orally, or intraperitoneally (into the stomach cavity). Extravascular
administration is typically described by adding an absorption compartment from
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which the drug is absorbed into plasma. As a second example, we consider the two
compartment model described by a system of two differential equations
x˙1 = −(ke + k12)x1 + k21x2, x1(0) = D
V
, (16)
x˙2 = k12x1 − k21x2, x2(0) = 0, (17)
where k12 and k21 are the transfer rate coefficients from x1 to x2 and vice versa, and
ke, D and V are the same as before. In this model, x1 is referred to as the central
compartment, usually representing plasma or serum, and x2 is called the peripheral
compartment, representing other tissues.
Nonlinear pharmacokinetic models also exist, such as models with saturable elim-
ination, i.e., if x denotes the drug concentration in plasma, then instead of x˙ = −kex
one has
x˙ = − Vmaxx
km + x
, (18)
where Vmax is the maximum elimination rate, and km is the Michaelis-Menten con-
stant, corresponding to the concentration at which elimination is at half of its max-
imum rate [49]. Another example of nonlinear pharmacokinetics occurs in so-called
target-mediated drug disposition models, where a drug molecule binds to a target,
forming a drug-target complex [42]. This leads to nonlinear elimination whether one
is considering the concentration of free, bound, or total drug.
7.4 Pharmacodynamic models
Pharmacodynamic models link the exposure of a drug, i.e., dose or concentration,
to a, usually desirable, effect of interest. Before considering models of tumor growth
specifically in the next section, we should mention two general models that are fre-
quently used in pharmacodynamics. The first is the so-called Emax-model, providing
a direct relationship between drug exposure C and effect E
E(C) =
EmaxC
n
ECn50 + C
n
, (19)
where C is the drug concentration (sometimes dose is used instead), Emax is the
maximum drug effect, EC50 is the concentration at which half of the maximum effect
is achieved, and n is the so-called Hill coefficient. In order to describe an inhibitory
drug effect one can instead consider K−E(C) where K ≥ Emax is a baseline constant.
The other classical example is the indirect response or turnover model for a quantity
R, described by a single differential equation
R˙ = kin − koutR, (20)
where kin is a production, or input rate, and kout is an elimination rate, and R denotes
some response variable of interest. A drug effect is then introduced as inhibition or
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stimulation of either kin or kout, e.g., kin 7→ kin(1 + E(C)) when production is
increased in the presence of a drug. Typically response is assumed to start in steady-
state, i.e., R(t0) = kin/kout.
7.5 Tumor growth models
We first consider models described by a single differential equation, and then proceed
to consider delays using chains of damage compartments, examples from the papers
included in this thesis, including how to incorporate radiation therapy. Finally, we
mention a cell cycle model used to analyze combination therapy in paper V.
7.5.1 Single-compartment models
We first consider tumor models consisting of a single state, where V denotes the
tumor volume, mass, or number of cells. These three quantities can be used inter-
changeably by assuming that the tumor is homogeneous with constant density ρ = 1.
The simplest model describes exponential growth with rate α, i.e., V˙ = αV , but more
generally we may consider a modified exponential growth given by
V˙ = G(V )V, V (t0) = V0, (21)
where V0 denotes the tumor volume at time t0. Popular choices for the function G
include G(V ) = α(1 − V/K), the logistic model, and G(V ) = α ln(K/V ), the so-
called Gompertz model, where in both cases the carrying capacity K represents the
maximum tumor volume [6]. These are both special cases of the generalized logistic
model given by
V˙ = αν
(
1−
(
V
K
)1/ν)
V, V (0) = V0, (22)
where the logistic model is obtained for ν = 1 and the Gompertz model is obtained
in the limit as ν → +∞. Another example is the Von Bertalanffy model [7] given by
V = αV 2/3 − βV, V (0) = V0, (23)
where β > 0 is the death rate of tumor cells. The exponent 2/3 in the growth
term is commonly explained as follows. Tumor growth depends on the nutritional
intake, which comes from the surface of the tumor. Given a spherical approximation
of the tumor it follows that the surface S ∝ V 2/3. However, cell death can occur
everywhere in the tumor and the death term is therefore proportional to volume. A
comparison of typical tumor trajectories for the exponential, Gompertz, logistic, and
van Bertalanffy models is shown in Figure 2.
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Figure 2: Illustration of the logistic (α = 1,K = 3000), Gompertz (α = 1,K = 3000), and
van Bertalanffy (α = 14.42, β = 1) models to describe saturable growth of tumor
volume.
7.5.2 Models with damage compartments
A common way to go from the single-compartment models of the previous section to
a multi-compartment model is to introduce a chain of damage compartment, repre-
senting dying cells in an increasingly degraded state [36, 25, 34, 66, 21, 47, 48, 50].
Such a chain has been used in papers I-IV. A typical model consists of a main com-
partment x1 of proliferating cells and n − 1 damage compartment x2, ...xn, and is
described by the equations
x˙1 = G(x;u), (24)
x˙i = gi−1(u)xi−1 − gi(u)xi, i = 2, ..., n, (25)
where G is the net growth function, which in general depends on the state vector x as
well as the drug concentration vector u, and gi is the transfer rate from compartment
xi to compartment xi+1, that may depend on the drug concentration u. The total
tumor volume is given by the sum over all compartments V =
∑
xi. In the absence of
drug provocation, a typical choice forG and gi is given byG(x) = kgx1, corresponding
to exponential growth, and gi = kk. Such sets of damage, or delay, compartments can
be interpreted as the lifespan of cells having a certain distribution, that is affected
by the introduction of anticancer agents [40]. A sequence of n damage compartments
with rate parameter kk is therefore described by a gamma distributed lifespan with
rate parameter kk and shape parameter n. Delay compartments are also commonly
used to describe delay in an input signal, i.e., to describe a process when it takes
time for an administered drug to properly enter the system [60].
In particular paper I features a four-compartment linear model, x˙ = Ax, where
the system matrix A is given by
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Figure 3: Compartment model used to describe tumor growth after intervention with ce-
tuximab and cisplatin combinations. The model consists of a main compartment
V1 of proliferating cells and three damage compartments V2, V3, and V4 that cells
go through before dying. Drug action of cetuximab is described as inhibition of
the growth rate kg using an Emax function, whereas drug action of cisplatin is
described by a linear stimulation of the natural kill rate kk.
A =

kgI(C1)− kkS(C2) 0 0 0
kkS(C2) −kk 0 0
0 kk −kk 0
0 0 kk −kk
 , (26)
where kg is the growth rate, kk is the natural death rate, I is an inhibitory Emax
function depending on the concentration of the drug cetuximab denoted by C1, and S
is a linear stimulatory function depending on the concentration of the drug cisplatin
denoted by C2. Here
I(C1) = 1− ImaxC1
IC50 + C1
, S(C2) = 1 + bC2, (27)
where Imax is the maximum achievable inhibition due to treatment with cetuximab,
IC50 is the concentration at which 50% of maximum inhibition is achieved, and b is
a pharmacodynamic potency parameter of cisplatin. An illustration of the model is
provided in figure 3.
Long-term tumor growth without drug intervention is given by the largest eigenvalue
of A, i.e., λ1 = kg − kk. One finds that an eigenvector corresponding to λ1 is given
by
vλ1 =
(
1,
kk
kg
,
(
kk
kg
)2
,
(
kk
kg
)3)
. (28)
21
Initial conditions for the system were therefore chosen to be proportional to long-
term growth. Thus, if V0 denotes the initial volume in the first compartment, x1,
then the initial distribution is given by x(0) = V0vλ1 .
7.5.3 Models of radiation therapy
Papers II-IV expand on this model by incorporating the effects of radiation treatment.
The most general of these is presented in Paper III, which is a linear impulsive model
(see equation (7)) with six states: x = (V1, U1, U2, V2, V3, V4), and where the system
matrix A is given by
A =

kgI(Dacc, C)− kk 0 0 0 0 0
0 −kg − kk 0 0 0 0
0 2kg −kk 0 0 0
0 kk kk −kk 0 0
0 0 0 kk −kk 0
0 0 0 0 kk −kk
 , (29)
and the jump matrices Bi = B are given by
B =

SF (D,C)− 1 0 0 0 0 0
1− SF (D,C) 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
 , (30)
where I(Dacc, C) is a long-term inhibition of tumor growth depending on the accu-
mulated radiation dose Dacc and the concentration of a radiosensitizing drug, C, at
the time of irradiation and is given by
I(Dacc, C) = exp (−(1 + aC)γDacc). (31)
Here, a is a pharmacodynamic potency parameter of the radiosensitizer, and γ is
a potency parameter associated with long-term radiation exposure. The function
SF (D,C) is the surviving fraction of cells given irradiation with dose D and simul-
taneous radiosensitizer concentration C and is given by
SF (D,C) = exp (−(1 + bC)(αD + βD2)), (32)
where b is a pharmacodynamic potency parameter of the radiosensitizer, and α and
β are the linear and quadratic constants from the linear-quadratic model of radio-
biology, see section 6.3. The model is illustrated in Figure 4. The idea of long-term
inhibition of growth is similar to a model by Querdani et al., used to describe anti-
angiogenetic treatment [56].
Similar models have been proposed for radiation therapy alone, and excluding
the long-term inhibition of growth, e.g., in the paper by Watanabe et al. where the
authors describe the response to a single dose of radiation [62]. A more detailed
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Figure 4: Tumor model for treatment with radiation and radiosensitizer combinations.
Upon irradiation, a fraction of cells are transferred from V1, the proliferating
compartment, to U1, where they are allowed up to one more cell division (and in
the process transferring the daughter cells to U2), before dying through a series
of damage compartment, V2, V3, and V4. The fraction of proliferating cells that is
transferred depends on the radiation dose according to the linear-quadratic model,
stimulated by the presence of radiosensitizer. The model also includes a perma-
nent inhibition of the growth rate kg depending on the accumulated radiation
dose, and the concentration of radiosensitizer at the time of irradiation.
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systems pharmacology model, supported by various in vitro and in vivo data, was
published by Checkley for combinations of radiation and a radiosensitizer [14]. That
model combines a cell cycle model, with a tumor model including an inner core and
an outer shell (see [19]), where also cells in the outer shell are sensitive to radiation.
7.5.4 Models of the cell cycle
Lastly, tumor growth is modeled as a linear cell cycle model in paper V. The model
consists of n states, x = (x1, ..., xn), and is described by the following system of
differential equations
x˙1 = 2knxn − k1x1, (33)
x˙i = ki−1xi−1 − kixi, i = 2, ..., n, (34)
where ki is the transfer rate from state xi to xi+1. After the last state, xn, mitosis
occurs, and the two daughter cells are transferred to x1. This model is illustrated in
Figure 5, taken from manuscript V. For this model we consider combination therapy
with m cytotoxic drugs, with corresponding concentration vector u = (u1, ..., um),
that act linearly on x. The model subject to drug provocation can be written
x˙ =
(
A−
m∑
i=1
Diui
)
x, (35)
where A is the system matrix for the system (34), given by
A =

−k1 0 . . . 0 2kn
k1 −k2 0 . . . 0
0 k2
. . .
...
... 0
. . .
. . . 0
0 . . . 0 kn−1 −kn
 , (36)
and Di are non-negative diagonal matrices whose entries Di,jj correspond to the drug
action of drug i on state xj . We can also collect the diagonal matrices Di as columns
of a full matrix B so that Bij = Di,jj . Then, the system may be written
x˙ = (A+ diag(Bu))x. (37)
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Figure 5: Illustration of a linear cell cycle model with n states, x1, ..., xn, with transfer
rates k1, ..., kn. During transfer between xn and x1 mitosis occurs and the cell
splits into two daughter cells. Cell death induced by a combination of m drugs
that may act differently on cells in different stages of the cell cycle, is indicated
with red arrows.
8 Mixed-effects modeling
In this section we consider the problem of model fitting and parameter estimation
for a model described by a system of ordinary differential equations and time-series
data from a population of individuals, e.g., from a xenograft experiment as described
earlier. We consider what is arguably the most appropriate and sophisticated frame-
work for population data, namely the mixed-effects modeling framework. The term
‘mixed-effects’ refers to the fact that effects, typically parameters in the model, are
composed of a fixed as well as a random component. E.g., we may want to describe
the tumor growth rate, denoted kg, with a lognormal distribution with parameters θ
and σ. Then we write kg = θe
η, where η is a normally distributed random variable
with zero mean and variance σ2
8.1 The mixed-effects framework
In a general setting, we consider population model described as a system of impulsive
differential equations
x˙(t) = f(x(t), u(t), θ, η, t), t ≥ 0, t 6= τi, (38)
x(τ+i ) = x(τ
−
i ) + gi(x(τ
−
i ), u(τ
−
i ), θ, η), (39)
x(0) = x0(u(t), θ, η), (40)
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where x is the vector of dependent variables, or states, u is an input, or control
vector, t is the dependent variable representing time, {τi}∞i=1 is a strictly increasing
sequence of fixed impulse times, not including the origin, such that τi → +∞ as
i → +∞, θ is a parameter vector that is common to the entire population, and η
is a multivariate normally distributed random vector with zero mean and covariance
matrix Ω = Ω(θ). The matrix Ω is symmetric and positive definite, and if it contains
any unknown parameters, these are included in the vector θ. When it is feasible, one
may assume that Ω is a diagonal matrix, since this greatly reduces the number of
parameters. In this case, η is a vector of independent normally distributed random
variables. For the tumor models considered in this thesis, x is a vector of states that
tumor cells can be inhabit, e.g., amounts of cells different stages of the cell cycle, or
simply proliferating or non-proliferating.
Let y be an observation vector modeled as
y = h(x, u, θ, η, t) + e, (41)
where h is a vector-valued (smooth) function and e is an error term, assumed to
be multivariate normally distributed with zero mean and covariance matrix R =
R(x, u, θ, η, t). Once again, if R contains any unknown parameters that need to be
estimated, these are included as part of the vector θ. For a xenograft study, only the
total tumor volume is measured, i.e., the sum of all states
y =
∑
i
xi + e, (42)
where we have used an additive error, R = σ2, in Paper I, a multiplicative error,
R = (
∑
i xi)
2
σ2 in paper II, and a combination of both R = σ21 + (
∑
i xi)
2
σ22 in
Paper III.
The parameter vector θ can be estimated using the maximum likelihood method.
Let dij denote an observation of individual i at time tji , and define the residual
ij = dij − E[yij ]. (43)
where E denotes expectation. The likelihood function for individual i, assuming ηi
are known, is given by
Li(θ) := p1(di|θ, ηi), (44)
where p1 is the probability density for the observations given θ and ηi, and is given
by
p1(di|θ, ηi) =
∏
j
1√
2pi detR
exp
(
−1
2
TijR
−1
ij ij
)
, (45)
where the product is taken over all observation times for individual i. Considering ηi
as a random vector, we can obtain the likelihood function for θ by marginalizing the
joint likelihood with respect to ηi using the law of total probability to obtain
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Li(θ) :=
∫
p1(di|θ, ηi) p2(ηi|θ) dηi, (46)
where p2 is the probability density of ηi given θ and is given by
p2(ηi|θ) = 1√
2pi det Ω
exp
(
−1
2
ηTi Ω
−1ηi
)
. (47)
The population likelihood function L is given as the product of the individual likeli-
hoods
L(θ) =
∏
i
Li(θ). (48)
Given the functional form of each individual likelihood, the population likelihood can
also be written in terms of the individual log-likelihood functions li according to
L(θ) =
∏
i
∫
exp (li) dηi, (49)
where li are given by
li =− 1
2
∑
j
(
TijR
−1
ij ij + ln det(2piRij)
)
(50)
− 1
2
ηTi Ω
−1
ij ηi −
1
2
ln det(2piΩ). (51)
Once θ has been estimated, we may obtain the optimal values for ηi, which we
denote by η∗i and refer to as the empirical Bayes estimates (EBEs) by maximizing
the individual likelihood for each individual in the population.
Several algorithms have been developed in order to maximize L(θ) including the
First Order Conditional Estimation (FOCE) method and the Stochastic Approxi-
mation Expectation Maximization (SAEM) algorithm. We give a brief overview of
the FOCE method, an implementation of which has been developed inhouse at the
Fraunhofer-Chalmers Centre using Wolfram Mathematica. For details, we refer to
the paper by Almquist et al. [4].
Since L does not have a closed-form solution for any reasonable practical problem,
we approximate the individual log-likelihood li using a second order Taylor expansion
in ηi around η
∗
i to give
l(θ) ≈ lF (θ) :=
∑
i
(
li(η
∗
i )−
1
2
ln det
−Hi(η∗i )
2pi
)
, (52)
where Hi is the Hessian matrix whose elements are given by [Hi]jk = ∂ηk∂ηj li. The
hessian matrices include terms involving first and second order partial derivatives
of ij and Rij . This makes them computationally expensive and an approximation
is therefore made by ignoring all second order terms. An argument in favor of this
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exclusion is that the expected value of these terms can be shown to be zero. It
should be noted that the residuals ij as well as the matrices Rij , and their partial
derivatives, generally depend on the state vector x and the state sensitivities, meaning
that an ODE system has to be solved when these are quantities are to be evaluated.
The optimization problem can be solved using a Quasi-Newton method such as
the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm [10], where, in order to
evaluate the population likelihood for a given θ, an inner optimization problem is
solved to find the corresponding η∗ . Derivatives can be approximated using finite-
difference, or be exactly computed using so-called sensitivity equations, derivatives of
the state vector x with respect to η and θ. We consider the technical details regarding
this particular implementation of the FOCE method using sensitivity equations to
be outside the scope of this thesis, and instead refer to the paper by Almquist et al.
[4].
8.2 Model evaluation
It is standard procedure to consider the precision of the parameter estimates θ ob-
tained from maximum likelihood estimation. This can be done in a variety of ways,
e.g., by bootstrapping, where data is re-sampled, with replacement, a large number
of times, N , yielding a sequence of estimates (θˆ1, ..., θˆN ) of (θ1, ..., θN ), from which
the sample variance for each component of θ can be estimated. This procedure is
computationally expensive, and we have therefore made use of the Fisher informa-
tion matrix I(θ) to estimate the relative standard error (RSE) of each parameter
estimate. The Fisher information is the Hessian of the (population) log-likelihood
function
I(θ)jk :=
∂2l(θ)
∂θj∂θk
. (53)
We remark that, as before, the partial derivatives can be computed approximately
using finite differences, or exactly using sensitivity equations [4]. The RSE for θi,
which we denote by RSE(θi), is then approximated by
RSE(θi) ≈ 100|θi| ×
√
[I(θ)−1]ii. (54)
A calibrated model can be evaluated by inspecting of the residuals and EBEs (η∗) for
trends. A typical indication that the model is not good enough could be that EBEs
are clustered with respect to the treatment groups.
Models can also be compared using the Akaike information criterion (AIC), which
is defined as
AIC = 2n− 2l(θ∗), (55)
where n is the total number of parameters in the model, and l(θ∗) is the maximum
log-likelihood value. AIC is a measure of the information lost when using a given
model to describe data, and weighs goodness-of-fit against model complexity [2].
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Thus, a model with a lower AIC value should be preferred over one with a higher
AIC value. Note that if two models have the same number of parameters, comparing
AIC values is equivalent to comparing likelihood values.
Finally, it is typical for a model to be evaluated using a technique known as Visual
Predictive Check (VPC). A VPC involves using the calibrated model to simulate
a large number of individuals (or identical studies) so that different percentiles in
the simulated data can be compared with the observations in the original data.
By simulating many different synthetic data sets with the same covariates as the
original data, it is also possible to construct confidence bands for different percentiles
(particularly the median) of the observed population. An example of a set of VPCs,
taken from paper III, is shown in Figure 6.
8.3 Naive pooled vs. Two-stage vs. Mixed-effects
Parameter estimation can be approached in different ways, and in this section we
compare mixed-effects modeling to two alternative techniques, the naive pooled ap-
proach and the two-stage approach for population modeling. We consider, in par-
ticular, the situation with data from a combination therapy (xenograft) experiment
with treatment groups including: a vehicle group, monotherapy groups with the dif-
ferent compounds, and combination treatments. For a thorough discussion of these
approaches see, e.g., [9].
The naive pooled approach treats all data from individuals in a treatment group
as though it came from the same individual. This leads to a simultaneous nonlinear
regression problem for N models, where N is the number of treatment groups, with
a common parameter vector θ to be estimated using e.g. maximum likelihood or the
least squares method. This approach does not quantify between-subject variability,
and is therefore more appropriate when there is little such variability, or to get a
rough estimate of the typical behavior. In contrast, when there is significant vari-
ability between individuals, which is the case for the animals treated with radiation
therapy that are described in this thesis, a naive pooled approach is less effective,
and moreover, quantifying and understanding the variability is important to avoid
future treatment failure.
The two-stage method is an approach for quantifying between-subject variabil-
ity that is simpler than mixed-effects modeling. The approach treats each subject
individually, and statistics, such as the sample mean and standard deviation, are
computed afterwards for the model parameters. This works well if there is a lot of
data from each individual, so that the parameter estimates have decent precision, but
does not work very well if for some individuals there is only one or a few measure-
ments. This can be somewhat remedied by only estimating a subset of the parameters
individually, and letting the rest be the same for the entire population. However, this
would require simultaneous fitting of all individuals, which is not significantly easier
than using mixed-effects modeling.
In conclusion, in this thesis we have used mixed-effects modeling since it is the
most sophisticated framework for treating between-subject variability, and it makes
use of the information in all data in the estimation of all model parameters. In
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Figure 6: Examples of visual predictive checks (VPCs) taken from paper III. The figure
shows simulated confidence regions for the 10th, 50th, and 90th percentiles ob-
tained by simulating a large number of data sets, for the treatment groups vehicle
(A), radiation only (B), radiation and low dose of radiosensitizer (C), and radi-
ation and high dose of radiosenzitier (D).
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contrast, a naive pooled approach would not have been adequate due to significant
variability, and the two-stage approach would have been similar to using a uniform
distribution compared to a lognormal distribution, the latter of which has the desir-
able properties of ensuring positivity and penalizing outliers.
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9 Tumor Static Exposure
In the absence of treatment cancerous tumor grow larger over time. Intervention with
an anti-cancer compound can slow down the cancerous growth, and in good cases even
reverse it. Starting with low exposures of the compound and gradually increasing it,
one may find a point when the tumor stops growing and starts shrinking instead. We
call such an exposure level the Tumor Static Exposure (TSE) of the given compound
and denote it by u∗. By this definition all exposures u less than u∗ will yield tumor
growth, and it is reasonable to assume that any u greater than u∗ results in tumor
shrinkage. Thus, u∗ divides all possible exposures, represented by the positive real
line [0,+∞) into two intervals, G := [0, u∗] and S := (u∗,+∞) that yield different
qualitative tumor evolutions.
The construction of TSE and the growth and shrinkage sets, G and S, can be
naturally extended to interventions with multiple anti-cancer agents. For two com-
pounds, with exposures u1 and u2, the TSE set is a curve consisting of pairs (u1, u2)
that separates the first quadrant of the exposure plane into a region of tumor growth
G and one of tumor shrinkage S, whereas for three or more compounds the TSE
set will be a (hyper-)surface in the first orthant. The case with two compounds is
illustrated in Figure 7, which is taken from Paper I.
It is clear that knowledge of TSE for a given combination is of considerable
therapeutic interest, since it would allow for treatment that results in a desirable
effect, i.e., tumor shrinkage, while avoiding toxic effects associated with overdosing.
As shall be discussed more later in this section, TSE can also be used optimize a
given combination and to compare and rank combinations against each other.
TSE can be difficult obtain experimentally, not only due to variability and un-
certainty in measurements, but also because it would require testing many different
exposure levels to sufficiently map out and identify the sets G and S, which be-
comes even more arduous for combination therapies. Therefore, it is convenient to
use modeling to make a prediction of TSE based on a smaller set of experiments.
Tumor Static Exposure and similar concepts are considered in all five papers
included in this thesis. These concepts have also been featured in a number of other
publications, see e.g., [48, 23, 34, 36, 37, 45]
9.1 Definition of Tumor Static Exposure
Consider a compartment model of a tumor described by an impulsive system of
autonomous differential equations as in equation (3) - (5), with fixed impulsive times,
a state vector x = (x1, ..., xn), and an input or exposure vector u = (u1, ..., um) that
is assumed to be constant. The components, ui, can e.g. be the (average) plasma
concentration of a particular compound, or the daily dose of radiation. Moreover, we
assume that xu = 0 is a solution to the system for any u. Define the shrinkage set
S := {u ∈ Rm+ : xu = 0 is a (locally) stable solution}. (56)
Recall that a solution solution ϕ(t) to a system of (impulsive) differential equations
is stable if any other solution ϕ(t) that starts near ϕ(t), remains close to ϕ(t) for
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Figure 7: Tumor Static Exposure curve for the model given by the system matrix (26),
for combinations of the compounds cetuximab and cisplatin, using the parame-
ter estimates from fitting the model to xenograft data. The shrinkage region S is
marked in green. The intersections of the TSE curve with the coordinate axes cor-
respond to the concentration resulting in tumor shrinkage when the corresponding
compound is administered as monotherapy.
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all t. More precisely, if for any  > 0 and t > 0 there exists a δ such that if ||ϕ(t0)−
ϕ(t0)|| < δ then ||ϕ(t)− ϕ(t)|| < .
If the system does not contain any jumps, or at least the jumps do not depend
on the exposure u, stability can be established by linearization and the Hartman-
Grobman theorem. Let Au be the linearization of the system dynamics f about the
origin. Then the origin is a stable equilibrium solution if all eigenvalues of Au have
negative real parts. This can be used to identify the shrinkage set S for the models
in papers I and V, which are already linear and do not feature radiation impulses.
For the radiation models in papers II-IV, however, one could use general definition of
stability above, which for a general impulsive system can be quite difficult. However,
the radiation models featured in this thesis have a main compartment V1 such that
if V1 → 0, as t → +∞, then the volumes of all other compartment also vanish.
Hence, the stability problem can be reduced to a single differential equation, and the
stability problem reduces to ensuring that the outflow from the main compartment
is greater than the inflow due to cell proliferation.
We can define the TSE set as the boundary of shrinkage set, i.e., TSE:= ∂S, and
the growth set G as the complement to S, i.e., G := Sc ∩ Rm+ . Thus, TSE divides
the positive orthant into the regions G and S. Exposure combinations u on the
TSE surface leads to stable, bounded disease, either at steady state, or exhibiting
oscillatory behavior.
To illustrate, we consider the set S for the model in paper I, is of the following
form
S = {(u1, u2) ∈ R20 : kgI(u1)− kkS(u2) < 0}, (57)
for some functions I and S. If I is a convex function and S is concave, it follows
immediately that S is a convex set. In particular, this is true for linear functions, or
Emax-type functions with Hill-coefficient n ≤ 1. The case I(u1) = 1− Imaxu
n1
1
IC
n1
50 +u
n1
1
and
1 +
Smaxu
n2
2
SC
n2
50 +u
n2
2
is illustrated in Figure 8 for different values of n1 and n2.
Paper V provides a generalization of when the shrinkage set is convex for more
general compartment models. Assume that the linearization (with respect to x) of a
non-impulsive system can be written
x˙ =
(
A−
m∑
i=1
Hi(ui)
)
x, x(0) = x0, (58)
where A is a matrix with non-negative offdiagonal entries (a so-called Meltzer ma-
trix) and Hi are diagonal matrices, whose components are convex functions of ui. It
then follows, as a corollary to a theorem first proved by Cohen (see [16]) regarding
convexity of the spectral radius for non-negative matrices, that the corresponding
shrinkage set
S := {u = (u1, ..., um) ∈ Rm+ : xu = 0 is a locally stable solution}, (59)
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Figure 8: Tumor Static Exposure curves for different values of the sigmoidicity parameter
n2. The other parameters were chosen as kg = 0.5, kk = 0.3, Imax = Smax =
IC50 = SC50 = n1 = 1. The figure illustrated that the TSE curves are convex
for n2 < 1, but not necessarily for n2 > 1.
is a convex set. Convexity is a nice property not only for optimization purposes, but
also it results from synergistic effects between treatment, by which we in this context
mean nonlinearities that reward combining compounds.
9.2 Uncertainty and Variability
Above, TSE was introduced based on a deterministic model with known parameters.
However, for practical applicability, parameters need to be estimated, which includes
a level of uncertainty in the estimates. Moreover, if a mixed-effects approach was
followed for model calibration based time series data, then between-subject variability
has also been quantified. In the context of TSE, it is desirable to incorporate such
variability and uncertainty, in order to understand how the outcome varies in a
population. In particular, we may want to predict tumor shrinkage, i.e., the set S,
not only for the typical individual, but for a larger percentage, say 95%, of the
population.
If the set S permits an analytic expression of the form
S = {u ∈ Rm+ : h(u, θ, η) < 0},
for some function h, where θ is a vector of population parameters (or, more pre-
cisely, their estimates), and η is a random vector with a known distribution, then
H = h(u, θ, η) defines a new random variable. In special cases, the distribution of H
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can be determined exactly, e.g., using the fact that the product (quotient) of two inde-
pendent log-normally distributed random variables is again log-normally distributed.
In general, Monte Carlo simulations can be used to compute the set Sα defined by
Sα := {u ∈ Rm+ : Pη(h(u, θ, η) < 0) = α}, (60)
for some α ∈ (0, 1). Alternatively, Sα may be approximately obtained by taking the
α-percentile among the TSE curves for the individuals in the observed population,
which can be computed using η∗i for each individual that were obtained by max-
imizing the individual log-likelihood given the final parameter estimates for θ. An
example, taken from paper II, is shown in Figure 9. Moreover, the estimated uncer-
tainty in the parameter vector θ can be used to construct a confidence region for Sα,
either by bootstrapping, or using the asymptotic normal distribution and the Fischer
information matrix I(θ).
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Figure 9: Individual TSE curves for the data modeled in paper II are shown in blue, whereas
the median TSE curve is shown in red. Using these, an approximation of the 95%
TSE curve can be constructed (red dashed).
9.3 Optimization and Ranking of Combinations
Given a cost function Ψ = Ψ(u), we can consider the optimization problem
min
u∈S
Ψ(u), (61)
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where the cost function reflects e.g., the toxicity associated with different expo-
sure combinations. Manuscripts IV and V consider this optimization problem us-
ing the simplest possible cost function, namely a linear one: Ψ(u) = αTu, where
α = (α1, ..., αm) is a vector of weights, reflecting the (relative) costs of the com-
pounds. In general, more complicated cost functions can be considered that include
e.g., damage to healthy tissue, body weight, or white blood cell count. Note that
convexity of S is a nice property for this optimization problem since if Ψ is also
convex, then any local optimum is also a global one.
Apart from quantifying optima, questions regarding its uniqueness and whether
u∗ > 0, i.e., whether it is optimal to use all compounds, are worthy of consideration.
Once an optimum, u∗, has been found, the optimal value Ψ∗ = Ψ(u∗) can be used to
compare the combination against combinations of different compounds, as we have
done in Paper IV for combinations of radiation with three different radiosensitizing
agents. Moreover, Paper V considers such an optimization problem for a model with
an arbitrary number of compounds, which could be thought of as including a large
number of compounds into the same model (which could in principle be done e.g.,
by simultaneous fitting of data from many different studies), and quantifies the op-
timum, its uniqueness, and which compounds are used in such an optimum. Thus,
besides optimization of a given combination, one could imagine using this optimiza-
tion problem to deselect compounds from consideration if they are not included in
the optimal solution.
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10 Summary of Papers
In this section, we provide summaries of the five papers that comprise this work. The
complete papers can be found appended at the end of this thesis.
10.1 Summary of Paper I
In the first paper, we construct a tumor growth inhibition (TGI) model for combina-
tions of the drugs cetuximab and cisplatin, and explore the concept of Tumor Static
Concentration (TSC) for drug combinations. Cetuximab is a monoclonal antibody
and an epidermal growth factor receptor (EGFR) inhibitor. Inactivation of EGFR,
an oncogene that is over-expressed in many cancer cases, should prevent uncontrolled
cell division and inhibit tumor growth. Cisplatin is a platinum-based chemotherapy
that interferes with DNA replication and kills the fastest proliferating cells.
A linear four compartment model with one proliferation state and three damage
compartments is used to describe xenograft data from a cetuximab-cisplatin study.
Drug action of cetuximab is described as inhibition of tumor growth rate, whereas
drug action of cisplatin was described as stimulation of cell death. New to this model
was also the inclusion of a natural death rate. Appropriate initial conditions are found
by computing the eigenvector associated with the only positive eigenvalue of the sys-
tem matrix for untreated tumors. Following a mixed-effects approach, model fitting
is shown to be adequate and all model parameters were estimated with acceptable
precision.
Tumor Static Concentrations are defined as the set of cetuximab-cisplatin con-
centration pairs (Ccetux, Cplat) leading to stable disease. Mathematically, this occurs
when the largest eigenvalue of the system matrix has a real part of zero. This leads
to a curve in the first quadrant of the CcetuxCplat concentration plane, called the
TSC curve, separating tumor growth from shrinkage. Convexity of the TSC curve for
cetuximab and cisplatin, as well as three alternative drug action combinations are
established as they are all on the form
αCACB + βCA + γCB = δ, (62)
for two drugs with concentrations CA and CB , which describes a hyperbola or a
straight line (if α = 0), whose intersections with the coordinate axes are given by
δ/β and δ/γ. The extension of the TSC curve to three or more compounds is briefly
considered, leading to hyper-surfaces in Rn.
10.2 Summary of Paper II
In the second paper, we construct a tumor model for combinations of ionizing ra-
diation (x-rays) and a radiosensitizer, and extend the TSC concept to account for
radiation. The radiosensitizer is a small molecule that interferes with the repair of
DNA damage caused by radiation, leading to cell death through e.g. apoptosis or
mitotic catastrophe.
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A system of impulsive differential equations is used to describe data from a
xenograft study. The system consists of a proliferating state, three damage damage
compartments, and two radiation compartments for lethally irradiated cells. Upon
irradiation, a fraction of proliferating cells, chosen according to the linear-quadratic
model of radio-biology, are transferred to the first radiation compartment, where they
are allowed up to one more cell division before dying through the chain of damage
compartments. The extra cell division ensures that the total tumor volume changes
smoothly over time. Presence of radiosenzitizer at the time of irradiation was de-
scribed as enhancing the radiation effect, as though a greater dose of radiation had
been given. Following a mixed-effects approach, model fitting is shown to be adequate
and all model parameters were estimated with acceptable precision.
TSC is generalized to Tumor Static Exposure (TSE), in order to describe radiation
therapy. A TSE curve is derived consisting of all combinations of daily radiation doses
and average radiosensitizer concentrations that lead to stable disease. The TSE curve
is shown to be convex and on the form
αD2RTCRS + βD
2
RT + γDRT + δCRS = , (63)
where DRT is the daily radiation dose and CRS is the daily average radiosensitizer
concentration. The model and TSE curve are validated by using a second data set
with different radiosensitizer dose, which, according to the TSE curve, was accurately
predicted to lead to slight tumor shrinkage.
10.3 Summary of Paper III
The fourth paper extends the model for radiation and radiosensitizing treatment
from paper II to account for long-term effects on tumor growth. The first radiation
effect, where a fraction of proliferating cells are allowed up to one more cell division
and subsequently died, is retained and a second radiation effect is incorporated into
the model whereupon the tumor growth rate, kg, is decreased depending on the
accumulated radiation dose. It is assumed that this effect is modulated depending on
the radiosensitizer concentration at the time of irradiation. Model fitting is shown to
be adequate and with reasonable parameter estimates and precision, using xenograft
data from a study with a treatment schedule of six weeks, similar to what is used in
the clinic.
A TSE curve is constructed based on the long-term reduction of growth rate
alone, consisting of all total (accumulated) radiation doses and simultaneous radiation
concentrations leading to a net growth rate of zero, i.e., when the growth rate kg was
equal to the natural death rate kk. The equation for the TSE curve can be written
on the form
αDRTCRS + βDRT = γ, (64)
where DRT is the total radiation dose, and CRS is the radiosensitizer concentra-
tion at the time of irradiation. Since the equation contains no terms in CRS alone,
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it is not possible to achieve tumor stasis or shrinkage with only radiosensitizer treat-
ment. The TSE curve is clearly convex, with CRT = 0 as an asymptote. Beyond the
TSE curve, changes in net growth rate depending on combinations of radiation and
radiosensitizer are considered and shown as a heat map as well as a three-dimensional
plot.
10.4 Summary of Paper IV
The third paper is an application of the radiation and radiosensitizer model from
Paper II to describe xenograft data using radiation therapy and three different ra-
diosensitizing compounds, which serves as further validation of the model. The paper
also considers the problem of comparing the three combinations (radiation plus ra-
diosensitizer A, B, or C), using TSE curves computed for each combination. For each
TSE curve, an optimum exposure pair (DRT , CRS) is computed by minimizing a lin-
ear combination of the drug exposures along the TSE curve. The minimum values
corresponding to each radiation and radiosensitizer combination is then compared in
order to rank the three combination therapies.
The paper also introduces Tumor Shrinkage Exposures (TSEdV ) corresponding
to those exposure combinations that result in a certain (relative) shrinkage rate, with
dV = 0 corresponding the the usual Tumor Static Exposure curve, and considers the
same optimization problem for different desired shrinkage rates. Results show that
the choice of radiosensitizer was independent of the desired shrinkage rate.
10.5 Summary of Paper V
The fifth paper considers a linear cell cycle model with n states subject to combi-
nation therapy with m compounds. Drug action is assumed to be linear and may
differ depending on the states of the cell cycle. Metabolic pressure associated with
chemotherapeutic treatment is represented by a linear combination of the drug expo-
sures, which is then minimized subject to a constraint of stable or regressive disease,
i.e., a condition that the largest eigenvalue of the system matrix has zero real part.
This constraint describes a TSE hypersurface in Rn+, which is shown to be convex.
Drug actions of the m compounds on the n states can be summarized by the drug
action matrix B such that Bij corresponds to the drug action of drug j on state i.
It is shown that if B has linearly dependent columns, an optimum exists where at
least one of the drug concentrations is zero, whereas if B has linearly independent
columns, a solution formula is prescribed. In the special case where each drug targets
a different, single, state, the result is similar to one of the classical proofs of the
inequality between the arithmetic and geometric means, whereas the more general
case is obtained by an invertible affine transformation.
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11 Discussion
The research described in this thesis aims to support discovery and development
of combination treatments in preclincal oncology using mathematical modeling and
simulation. This research is summarized in five appended manuscripts, and in the
previous sections of this thesis. The focus has been on three research questions (see
section 3) and there is a logical progression - threads connecting the five manuscripts.
First, a standard model was adjusted to account for natural cell death, fitted to
xenograft data for established compounds, and using this model the TSE concept
was derived and analyzed. Next, the model, as well as the TSE concept was extended
to radiation therapy, and was later adjusted to account for long-term treatment.
Applications of the TSE concept were also explored: to optimize a given combination,
and to compare/rank different combinations. Lastly, to reflect tumor heterogeneity,
a theoretical investigation of TSE was performed for a cell cycle model, in which
combination therapy with an arbitrary number of anticancer drugs was considered.
11.1 Main contributions and research questions
The three research questions (section 3) relate to improving or extending existing
models (Q1), what we do with the models (Q2), and how uncertainty and variability
is taken into account (Q3). These can be connected to the three main contributions
(section 4) in the following way.
The first main contribution, inclusion of natural cell death, is an example of
improving, making existing models more biologically feasible (Q1). Similarly, the
development of radiation models for short-term and long-term treatment, with and
without radiosensitizing treatment, also addresses Q1.
The TSE concept, which is featured in all five manuscripts, is an example of
a model-based tool and therefore addresses Q2. How to define and construct TSE
curves is addressed in manuscripts I-III, whereas manuscripts IV and V illustrate
have TSE can be used. Moreover, the use of nonlinear mixed-effects modeling in
general, and the quantification of between-subject variability in TSE in particular,
are examples of how this research has addressed Q3.
11.2 Conclusions
The most important conclusions become apparent when looking at the research ques-
tions, main contributions, and the discussion above. Throughout this thesis, we have
emphasized how relatively simple mathematical models can be used to support pre-
clinical drug discovery and development. Models have been development for different
treatment modalities, with a particular focus of radiation, that have a simple and
generic structure such that they can be reused for different compounds and combi-
nations without making too many changes.
We have focused on TSE, defined using the appropriate stability notion, as a
useful and widely applicable endpoint with a clear biological interpretation. We have
explored how to interpret and use the shape of the TSE surface with respect to
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compound selection, optimization, and how to account for variability. Moreover, the
usefulness of mixed-effects modeling for quantification of between-subject variability,
to be able to predict tumor shrinkage in a large portion of the population, has been
consistent throughout all model fitting in this thesis.
11.3 Future work and open problems
The work that has been conducted during this project poses a number of new ques-
tions, and there are several extensions of existing concepts that have not been fully
explored.
Firstly, the main concepts proposed in this thesis, i.e., those related to radiation
modeling, and the TSE concept, have yet to be used in practice when designing
and analyzing new experiments. Moreover, the predictive power of these concepts
could be tested using e.g. published data on combinations with a large number of
experiments using different exposures.
Secondly, the usefulness of the TSE concept in translational efforts in vitro - in
vivo, as well as across species (with understandable ethical limitations), and, ulti-
mately, to humans, have been treated only superficially in discussion form. A first
step in this direction would be to find combinations with the right data (in vitro - in
vivo - clinical), such that TSE surfaces can be generated for each type of data and
be compared.
The TSE concept itself could likely be extended, particularly with respect to
variability. Stability, e.g., the largest eigenvalue of the system matrix, could be treated
formally as a function of a random parameter vector such that various properties of
the resulting statistical quantity can be examined, including mean, variance, but also
e.g., higher moments.
The radiation models proposed in papers II and III could also be extended, partic-
ularly to describe the repair process of DNA damage, something that was attempted
during this project, but did not seem feasible using only data about tumor volume
over time. Analytic expressions and approximations for the chains of damage com-
partments (V2, V3, ...), as well as radiation compartments (U1, U2, ...), could also be
investigated and tested to see if it makes parameter estimation faster and/or easier.
Lastly, the models used in this thesis have been exclusively ordinary differential
equations, but the erratic behavior of the time series for irradiated animals may
suggest that stochastic differential equations could help provide a good fit to data.
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